Current Report Filing (8-k)
16 December 2022 - 12:08AM
Edgar (US Regulatory)
0001708527
false
0001708527
2022-12-13
2022-12-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 13, 2022
AZIYO BIOLOGICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39577 |
|
47-4790334 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
12510 Prosperity Drive, Suite 370
Silver Spring, MD 20904
(Address of principal executive offices) (Zip
Code)
(240) 247-1170
(Registrant’s telephone number, include
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbols |
|
Name of each exchange on which
registered |
Class A
Common Stock, $0.001 par value per share |
|
AZYO |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of
a Registrant. |
On December 13, 2022, Aziyo Biologics, Inc. (the
“Company”) elected to draw the additional term loan of $4.0 million (the “Subsequent Term Loan”) under its previously
disclosed Credit Agreement, dated as of August 10, 2022 (as amended, restated, supplemented, or otherwise modified prior to the date hereof,
the “Credit Agreement”), by and among the Company, as the Borrower, and its subsidiaries, as the other loan parties, the financial
institutions party thereto from time to time as lenders, and SWK Funding LLC, as administrative agent and collateral agent for all lenders.
Following the funding of the Subsequent Term Loan, as of the date hereof, the Company had borrowings under the Credit Agreement of $25.0
million, consisting of an initial term loan of $21.0 million, which was funded on August 10, 2022, and the $4.0 million of the Subsequent
Term Loan, plus approximately $0.3 million in additional outstanding principal balance from the accrued interest on the initial term loan
which the Company elected to be “paid in kind” in accordance with the terms of the Credit Agreement.
The material terms of the Credit Agreement are
described under Item 1.01 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 15, 2022, Item 1.01 of the Company’s Current Report on Form 8-K filed with the SEC on November 28, 2022, and Item 1.01
of the Company’s Current Report on Form 8-K filed with the SEC on December 5, 2022, and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AZIYO BIOLOGICS, INC. |
|
|
|
Date: December 15, 2022 |
By: |
|
/s/ Matthew Ferguson |
|
|
|
Matthew Ferguson |
|
|
|
Chief Financial Officer |
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2023 to Mar 2024